In Elan's primary analysis, they used a linear model to measure benefit of Bapineuzumab over PBO, instead of calculating benefit on actual observed data.
I do not understand precisely what this means. Can you elaborate?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”